Trials / Conditions / Unresectable Malignant Neoplasm

Unresectable Malignant Neoplasm

17 registered clinical trials studyying Unresectable Malignant Neoplasm — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Completed	Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivol NCT05308966	Groupe Francais De Pneumo-Cancerologie	—
Unknown	Colorectal Metastasis and Liver Transplantation With Organs From Deceased Donors NCT04870879	Azienda Ospedaliera di Padova	N/A
Completed	A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer NCT04207918	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Phase 2
Recruiting	Chemoradiotherapy in Unresectable Esophageal Cancer NCT04278287	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Phase 1 / Phase 2
Unknown	ImmunoPET With an Anti-CD8 Imaging Agent NCT04029181	University Medical Center Groningen	Phase 1 / Phase 2
Completed	Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer NCT03777813	UNICANCER	Phase 2
Withdrawn	QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. NCT03647423	ImmunityBio, Inc.	Phase 1 / Phase 2
Completed	A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumor NCT03238027	Syndax Pharmaceuticals	Phase 1
Terminated	Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Tre NCT03240861	Jonsson Comprehensive Cancer Center	Phase 1
Completed	Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors NCT03108131	M.D. Anderson Cancer Center	Phase 2
Completed	Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by S NCT02583269	Wake Forest University Health Sciences	Phase 1
Terminated	Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Remove NCT02566421	Wake Forest University Health Sciences	N/A
Completed	Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Rem NCT02540876	University of Chicago	Phase 1
Completed	Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma NCT02306850	St. Louis University	Phase 2
Terminated	Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain NCT01846429	H. Lee Moffitt Cancer Center and Research Institute	Phase 1
Completed	Bevacizumab in Combination With Chemotherapy in Patients With Advanced or Recurrent Non-squamous NSCLC NCT01963351	University of Athens	—
Active Not Recruiting	Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be NCT01366144	National Cancer Institute (NCI)	Phase 1